New answer by Medical Oncologist at University of Texas MD Anderson Cancer Center (May 2, 2022)
I think it is reasonable to use the KEYNOTE-522 regimen for a patient with stage IIIB breast can with a tumor that is ER-low (<10%), PR+ and HER2-negative, but with many ca...